Skip to main content

On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance

Buy Article:

$48.00 plus tax (Refund Policy)

Abstract:

Summary.

Gasparini and Eisele (2000, Biometrics56, 609–615) propose a design for phase I clinical trials during which dose allocation is governed by a Bayesian nonparametric estimate of the dose-response curve. The authors also suggest an elicitation algorithm to establish vague priors. However, in situations where a low percentile is targeted, priors thus obtained can lead to undesirable rigidity given certain trial outcomes that can occur with a nonnegligible probability. Interestingly, improvement can be achieved by prescribing slightly more informative priors. Some guidelines for prior elicitation are established using a connection between this curve-free method and the continual reassessment method.

Keywords: Bayesian nonparametric estimation; Continual reassessment method

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.0006-341X.2002.00237.x

Affiliations: Division of Biostatistics, School of Public Health, Columbia University, New York, New York 10032, U.S.A., Email: cheung@biostat.columbia.edu

Publication date: March 1, 2002

bpl/biom/2002/00000058/00000001/art00029
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more